Associated Papers
No evidence for the LRRK2 p.L1795F variant in a Southern Italian cohort with Parkinson's disease.
Gagliardi M et al.
Gene, 2026
The LRRK2 G2385R Exonic Variant: A Potential Genetic Disease Modifier of Multiple System Atrophy?
Kouki N et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2026
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Multiple system atrophy: advances in pathogenesis and emerging therapeutic strategies.
Chen Z et al.
Journal of Neurology, 2025
Bridging pleiotropic mechanisms in leprosy type-1 reactions and neurodegenerative diseases.
Fava VM et al.
Scientific Reports, 2025
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation.
Liu J et al.
Science Advances, 2025
Genetic mutations in lymphocytic variant of hypereosinophilic syndrome: study of five siblings.
Walkenhorst M et al.
Frontiers in Medicine, 2025
The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity.
Kars ME et al.
Genome Medicine, 2024
ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages.
Wallings RL et al.
Molecular Therapy. Nucleic Acids, 2023
Impaired dopamine release in Parkinson's disease.
Cramb KML et al.
Brain : a Journal of Neurology, 2023
Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
Koga S et al.
Acta Neuropathologica Communications, 2023
LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X et al.
Biomolecules, 2023
Allele-dependent interaction of LRRK2 and NOD2 in leprosy.
Dallmann-Sauer M et al.
Plos Pathogens, 2023
Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson's Disease.
Grigor'eva EV et al.
International Journal of Molecular Sciences, 2023
The genetic basis of multiple system atrophy.
Tseng FS et al.
Journal of Translational Medicine, 2023
The Etiology of Parkinson's Disease: New Perspectives from Gene-Environment Interactions.
Bogers JS et al.
Journal of Parkinson's Disease, 2023
PSEN2 Thr421Met Mutation in a Patient with Early Onset Alzheimer's Disease.
Yang Y et al.
International Journal of Molecular Sciences, 2022
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Genomic, transcriptomic, and metabolomic profiles of hiPSC-derived dopamine neurons from clinically discordant brothers with identical PRKN deletions.
Cukier HN et al.
Npj Parkinson's Disease, 2022
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
Lake J et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2022
Non-polyalanine repeat mutation in PHOX2B is detected in autopsy cases of sudden unexpected infant death.
Ueda A et al.
Plos One, 2022
Deep resequencing identifies candidate functional genes in leprosy GWAS loci.
Fava VM et al.
Plos Neglected Tropical Diseases, 2021
Reassessing neurodegenerative disease: immune protection pathways and antagonistic pleiotropy.
Provenzano F et al.
Trends in Neurosciences, 2021
Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient.
Bresadola L et al.
International Journal of Molecular Sciences, 2021
Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N et al.
Human Molecular Genetics, 2021
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?
Herrick MK et al.
Npj Parkinson's Disease, 2021
Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG et al.
Parkinsonism & Related Disorders, 2021
A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).
Low JL et al.
Ebiomedicine, 2021
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism.
Chittoor-Vinod VG et al.
International Journal of Molecular Sciences, 2021
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
Kline EM et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2021
Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease.
Torrealba-Acosta G et al.
Frontiers in Neurology, 2021
Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo.
Ikezu T et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Hemasphere, 2020
Pathogenic PSEN1 Thr119Ile Mutation in Two Korean Patients with Early-Onset Alzheimer's Disease.
Bagyinszky E et al.
Diagnostics (basel, Switzerland), 2020
Is there an antagonistic pleiotropic effect of a LRRK2 mutation on leprosy and Parkinson's disease?
Zhang DF et al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson's disease in Black South African and Nigerian patients.
Oluwole OG et al.
Bmc Medical Genetics, 2020
Leucine Rich Repeat Kinase 2 and Innate Immunity.
Ahmadi Rastegar D et al.
Frontiers in Neuroscience, 2020
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease.
Rideout HJ et al.
Frontiers in Neuroscience, 2020